Dentium CO., LTD (KRX:145720)
56,000
+400 (0.72%)
At close: Oct 28, 2025
Dentium CO., LTD Revenue
Dentium CO., LTD had revenue of 82.25B KRW in the quarter ending June 30, 2025, a decrease of -26.34%. This brings the company's revenue in the last twelve months to 372.49B, down -9.68% year-over-year. In the year 2024, Dentium CO., LTD had annual revenue of 407.81B with 3.72% growth.
Revenue (ttm)
372.49B
Revenue Growth
-9.68%
P/S Ratio
1.30
Revenue / Employee
436.68M
Employees
853
Market Cap
482.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 407.81B | 14.62B | 3.72% |
| Dec 31, 2023 | 393.19B | 37.32B | 10.49% |
| Dec 31, 2022 | 355.87B | 64.34B | 22.07% |
| Dec 31, 2021 | 291.53B | 61.78B | 26.89% |
| Dec 31, 2020 | 229.75B | -22.84B | -9.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |